Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6NIH 1NETWORK 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 349Neoplasm Metastasis 31Stomach Neoplasms 30HER2-positive Breast Cancer 19Neoplasms 16Breast Neoplasms, Male 16Brain Neoplasms 13Inflammatory Breast Neoplasms 12Esophageal Neoplasms 10Colorectal Neoplasms 10Triple Negative Breast Neoplasms 8Adenocarcinoma 7Prostatic Neoplasms 6Cardiotoxicity 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Lung Neoplasms 5Carcinoma, Ductal, Breast 5Biliary Tract Neoplasms 5Salivary Gland Neoplasms 4Pathologic Complete Response 4Pancreatic Neoplasms 4Meningeal Neoplasms 4Colonic Neoplasms 4Breast Diseases 4Recurrence 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Gallbladder Neoplasms 3Carcinoma, Lobular 3

Interventions

Echocardiography 14Doxorubicin 10Exercise 9Electrocardiography 7Trastuzumab 6Cyclophosphamide 5Carvedilol 5Docetaxel 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Magnetic Resonance Spectroscopy 2Ivabradine 2High-Intensity Interval Training 2Exercise Test 2Chemoradiotherapy 2Blood Specimen Collection 2Bisoprolol 2Antineoplastic Agents 2Anthracyclines 2sulforaphane 1schizandrin 1pegfilgrastim 1nicotinamide-beta-riboside 1mitoquinone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Cardiotoxicity × Trastuzumab × Clear all
NCT04928261 2026-01-22

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
52 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT04962425 2021-07-15

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Peking University Third Hospital

Unknown
240 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT04961307 2021-07-14

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Peking University Third Hospital

Unknown
30 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT00875238 2018-02-19

PACE in BC

Vanderbilt University Medical Center

Completed
133 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT00377780 2015-09-23

MYOHERTAX

Catharina Ziekenhuis Eindhoven

Phase 2 Terminated
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡